Major histocompatibility complex–T-cell receptor complex recognizing M72 epitopes (MHC–TCR (M72))

The Major histocompatibility complex (MHC)–T-cell receptor (TCR) complex recognizing M72 epitopes is a critical immunological assembly involved in the adaptive immune response against Mycobacterium tuberculosis [1]. M72 is a recombinant fusion protein consisting of two immunogenic antigens, Mtb32A (Rv0125) and Mtb39A (Rv1196), which are processed by antigen-presenting cells and displayed on MHC molecules [3]. The resulting MHC-peptide complex is recognized by specific TCRs on the surface of T lymphocytes, primarily CD4+ T cells, leading to their activation and proliferation [2]. This interaction is the primary mechanism by which the M72/AS01E vaccine candidate elicits protective immunity, characterized by the production of Th1-type cytokines such as interferon-gamma and tumor necrosis factor-alpha [1]. By targeting this complex, the vaccine aims to enhance the host's ability to control or eliminate the tuberculosis pathogen [4]. Clinical studies have demonstrated that the formation and activation of this complex are associated with significant protection against the development of active pulmonary tuberculosis in individuals with latent infection [2]. The AS01E adjuvant system further modulates this interaction by enhancing the recruitment and activation of antigen-presenting cells [1]. Overall, this complex represents a pivotal target for next-generation tuberculosis vaccines aimed at inducing robust cellular immunity [3].

Other names

M72-specific TCR-MHC complexMtb32A-Mtb39A-specific TCR-MHC complexM72-peptide-HLA complexM72-specific T-cell receptor complex

Vaccine-induced stimulation of T-cell mediated immunity through the recognition of M72-derived peptides presented by MHC molecules by specific T-cell receptors.